Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director | September 30, 2026 | October 03, 2026 |
| GE HealthCare Technologies Inc.GEHC · Entity 1711 | Director · President and CEO | September 03, 2026 | September 04, 2026 |
| GENERAL ELECTRIC COGE · Entity 2813 | Senior Vice President | March 01, 2022 | March 04, 2022 |
| INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707 | Director · President & CEO | September 02, 2021 | September 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 74,077.176 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 560.897 · Balance 74,077.176 F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
GE HealthCare Technologies Inc.
Report date September 03, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 241,606 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Tax withholding · Disposed 6,303 · Balance 241,606 F1: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Withholding of shares of GE HealthCare Technologies Inc. common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
GENERAL ELECTRIC CO
Report date March 01, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,443 |
Reported balance
After 2022-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 14,443 · Balance 14,443 F1: 1 for 1 F2: The Restricted Stock Units vest and the Stock Options become exercisable, in two equal installments of 50% each on the second and third anniversary of the grant date |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $92.23 · Expires 2032-03-01 | Direct | 63,044 |
Reported balance
After 2022-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-01 · Grant · Acquired 63,044 · Balance 63,044 F2: The Restricted Stock Units vest and the Stock Options become exercisable, in two equal installments of 50% each on the second and third anniversary of the grant date |
Filing footnotes · ownership attribution and instrument terms
F1: 1 for 1
F2: The Restricted Stock Units vest and the Stock Options become exercisable, in two equal installments of 50% each on the second and third anniversary of the grant date
INTEGRA LIFESCIENCES HOLDINGS CORP
Report date September 02, 2021 · Filed September 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,713 |
Ending reported balance
After 2021-09-03 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2021-09-02 · Exercise / conversion · Acquired 71,829 · Balance 288,542 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Row 2 · 2021-09-02 · Sale · Disposed 71,829 · Balance 216,713 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F2: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.34 to $76.465 per share of common stock. Row 3 · 2021-09-03 · Exercise / conversion · Acquired 46,605 · Balance 263,318 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Row 4 · 2021-09-03 · Sale · Disposed 46,605 · Balance 216,713 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.40 to $76.09 per share of common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.88 · Expires 2022-03-06 | Direct | 46,605 |
Reported balance
After 2021-09-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-09-02 · Exercise / conversion · Disposed 71,829 · Balance 46,605 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4: One-third of the stock options vested on the first anniversary of the grant date of March 6, 2014 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the third anniversary of the grant date. F5: These options were previously reported as covering 56,727 shares at an exercise price of $48.27 per share, but were adjusted pursuant to the anti-dilution provisions of the award in connection with the separation of SeaSpine Holdings Corporation on July 1, 2015. F6: In accordance with terms of the stock option plan, the exercise price of the options and the number of shares subject to the options have been adjusted to reflect the two-for-one stock split of the Issuer's common stock that occurred on December 21, 2016. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.88 · Expires 2022-03-06 | Direct | 0 |
Reported balance
After 2021-09-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-09-03 · Exercise / conversion · Disposed 46,605 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F4: One-third of the stock options vested on the first anniversary of the grant date of March 6, 2014 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the third anniversary of the grant date. F5: These options were previously reported as covering 56,727 shares at an exercise price of $48.27 per share, but were adjusted pursuant to the anti-dilution provisions of the award in connection with the separation of SeaSpine Holdings Corporation on July 1, 2015. F6: In accordance with terms of the stock option plan, the exercise price of the options and the number of shares subject to the options have been adjusted to reflect the two-for-one stock split of the Issuer's common stock that occurred on December 21, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
F2: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.34 to $76.465 per share of common stock.
F3: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $75.40 to $76.09 per share of common stock.
F4: One-third of the stock options vested on the first anniversary of the grant date of March 6, 2014 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the third anniversary of the grant date.
F5: These options were previously reported as covering 56,727 shares at an exercise price of $48.27 per share, but were adjusted pursuant to the anti-dilution provisions of the award in connection with the separation of SeaSpine Holdings Corporation on July 1, 2015.
F6: In accordance with terms of the stock option plan, the exercise price of the options and the number of shares subject to the options have been adjusted to reflect the two-for-one stock split of the Issuer's common stock that occurred on December 21, 2016.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2016 Filed Apr 5, 2016 20:59 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 2,188.47 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-16-000388 · wf-form4_145988994999048.xml · derivative · entry 1 Arduini Peter J · CIK 0001323134 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,188.47 Underlying: Common Stock, $0.10 par value · 2,188.47 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · shares: Represents pro rata portion of the 2016 annual Deferred Share Units awards granted to the Company's directors. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.